WO2024069240A3 - Thérapie de combinaison de protéines de fusion se liant à cd38 - Google Patents
Thérapie de combinaison de protéines de fusion se liant à cd38 Download PDFInfo
- Publication number
- WO2024069240A3 WO2024069240A3 PCT/IB2023/000653 IB2023000653W WO2024069240A3 WO 2024069240 A3 WO2024069240 A3 WO 2024069240A3 IB 2023000653 W IB2023000653 W IB 2023000653W WO 2024069240 A3 WO2024069240 A3 WO 2024069240A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion protein
- binding fusion
- cancer
- combination therapy
- protein combination
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 101150002659 CD38 gene Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 abstract 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 2
- 208000034578 Multiple myelomas Diseases 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102100040018 Interferon alpha-2 Human genes 0.000 abstract 1
- 108010079944 Interferon-alpha2b Proteins 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960002438 carfilzomib Drugs 0.000 abstract 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 abstract 1
- 108010021331 carfilzomib Proteins 0.000 abstract 1
- 229940124622 immune-modulator drug Drugs 0.000 abstract 1
- 229960004942 lenalidomide Drugs 0.000 abstract 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 abstract 1
- 229960000688 pomalidomide Drugs 0.000 abstract 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
- C12Y302/02005—NAD+ nucleosidase (3.2.2.5)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des méthodes de traitement du cancer (par exemple, un cancer exprimant CD38 tel qu'un myélome multiple) à l'aide d'une protéine de fusion se liant à CD38 comprenant un anticorps anti-CD38 fusionné à une ou plusieurs protéines d'interféron alpha-2b atténuées en combinaison avec un ou plusieurs (par exemple, un, deux ou plus) agents pour traiter le cancer. Dans certains modes de réalisation, le cancer est un myélome multiple. Dans certains modes de réalisation, lesdits un ou plusieurs agents comprennent un médicament immunomodulateur (par exemple, le lénalidomide et/ou le pomalidomide) et/ou des inhibiteurs de protéasome (par exemple, le bortézomib et/ou le carfilzomib).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263411286P | 2022-09-29 | 2022-09-29 | |
US63/411,286 | 2022-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024069240A2 WO2024069240A2 (fr) | 2024-04-04 |
WO2024069240A3 true WO2024069240A3 (fr) | 2024-05-23 |
Family
ID=89378574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/000653 WO2024069240A2 (fr) | 2022-09-29 | 2023-09-28 | Thérapie de combinaison de protéines de fusion se liant à cd38 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024069240A2 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012041800A1 (fr) * | 2010-09-27 | 2012-04-05 | Morphosys Ag | Utilisation d'un anticorps anti-cd38 et de lénalidomide ou de bortézomib pour traiter le myélome multiple et le lymphome non hodgkinien |
US20150313965A1 (en) * | 2014-05-01 | 2015-11-05 | Teva Pharmaceuticals Australia Pty, Ltd | Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1360189A1 (fr) | 2001-01-25 | 2003-11-12 | Millennium Pharmaceuticals, Inc. | Formulation de composes d'acide boronique |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
BR112017008880A2 (pt) | 2014-10-29 | 2018-07-10 | Teva Pharmaceuticals Australia Pty Ltd | variantes de interferon a2b |
-
2023
- 2023-09-28 WO PCT/IB2023/000653 patent/WO2024069240A2/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012041800A1 (fr) * | 2010-09-27 | 2012-04-05 | Morphosys Ag | Utilisation d'un anticorps anti-cd38 et de lénalidomide ou de bortézomib pour traiter le myélome multiple et le lymphome non hodgkinien |
US20150313965A1 (en) * | 2014-05-01 | 2015-11-05 | Teva Pharmaceuticals Australia Pty, Ltd | Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof |
Non-Patent Citations (1)
Title |
---|
SARAH L. POGUE ET AL: "Targeting Attenuated Interferon-[alpha] to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity", PLOS ONE, vol. 11, no. 9, 9 September 2016 (2016-09-09), pages e0162472, XP055637284, DOI: 10.1371/journal.pone.0162472 * |
Also Published As
Publication number | Publication date |
---|---|
WO2024069240A2 (fr) | 2024-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220396A (es) | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos | |
NO20070052L (no) | Fremgangsmate for behandling av multippel sklerose | |
MX2021008267A (es) | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. | |
DE60229979D1 (fr) | ||
MX2023002540A (es) | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular. | |
MX2021008268A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
Stoitzner et al. | Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors | |
MX2022009100A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. | |
Sperling et al. | Facts and hopes in multiple myeloma immunotherapy | |
AR115721A1 (es) | Anticuerpos que comprenden un polipéptido insertado en la región marco 3 | |
MX2021013825A (es) | Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular. | |
MX2021004916A (es) | Nuevas composiciones proteicas de diseño idóneo. | |
MX2021009079A (es) | Metodos para tratar el mieloma multiple. | |
MX2022013251A (es) | Compuestos de heteroaril carboxamida de 5 miembros para el tratamiento de vhb. | |
MX2021002208A (es) | Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80. | |
WO2024069240A3 (fr) | Thérapie de combinaison de protéines de fusion se liant à cd38 | |
TW202430548A (zh) | Cd38結合融合蛋白組合療法 | |
MX2021007047A (es) | Formulaciones de anticuerpos. | |
WO2020180712A8 (fr) | Anticorps anti-tnfr2 et leurs utilisations | |
MX2018010836A (es) | Conformeros abiertos hla-b57. | |
WO2024073716A3 (fr) | Thérapie combinatoire de protéines de fusion se liant à cd38 | |
JOP20210247A1 (ar) | علاج الصداع باستخدام أجسام مضادة لـ cgrp | |
MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
MX2016009887A (es) | Procedimiento para el tratamiento de enfermedades infecciosas utilizando una composicion que comprende inmunoglobulina m (igm) derivada de plasma. | |
MX2023010567A (es) | Variantes de anticuerpos no activadoras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23828792 Country of ref document: EP Kind code of ref document: A2 |